

HORIZON

EUROPE



MISSION CANCER: IMPLEMENTIERUNGSPLÄNE UND KOMMENDE AUSSCHREIBUNGSTHEMEN

Ines Haberl | FFG, Nationale Kontaktstelle Gesundheit
13.12.2021 | Join our Community: 5 Missionen für Europa



CANCER IN HORIZON EUROPE

Cluster 1: Health => Calls for cooperative projects

Partnership Initiatives

- Innovative Health Initiative
- Personalisierte Medizin
- Transformation of Health & Care Systems
- Rare diseases
- Assessment of Risks from Chemicals

IMI
Oncology Portfolio

Pillar Excellent Science – mostly bottom up

- ERC
- Marie Curie (MSCA)
- Research Infrastructures

Mission Cancer

Pillar Innovative Europe – mostly bottom up

- EIC – Pathfinder, Transition and Accelerator

**EU4Health Programme
(DG Sante)**

**Europe's Beating
Cancer Plan**

**Digital Europe
Programme**

CONQUERING CANCER – MISSION POSSIBLE




Figure 1. Intervention areas for action

Ziel: „By 2030, more than 3 million more lives saved, living longer and better”

5 intervention areas

13 Patients/Citizen-centered recommendations

Source: [Mission Cancer](#)

MISSION CANCER IMPLEMENTIERUNGSPLAN

- Konzept für die Umsetzung der Mission, insbesondere in den ersten drei Jahren 2021-2024.
- Basierend auf den Empfehlungen des Mission Boards und enthält Einzelheiten:
 - zum **politischen Kontext**
 - zur **Interventionslogik, den spezifischen Objectives, den Durchführenden und zu Zeitplänen**
 - zum **Budget**
 - zu **Synergien** mit andern Programmen, Initiativen, Partnerschaften etc.
 - zur **internationaler Kooperation**
 - zur Missions-spezifischen **Governance**
 - zum **Monitoring**
 - zu **Citizen Engagement** und **Kommunikationsstrategie**
- Ein lebendes Dokument, das laufend aktualisiert werden soll

MISSION CANCER IMPLEMENTIERUNGSPLAN

Specific Objectives

1. Improve understanding of cancer
2. Prevention, screening & early detection
3. Optimise diagnostics and treatment
4. Support quality of life

Operational objectives (transversal):

- Foster innovation through generation of knowledge and evidence
- Promote innovation, test, validate, demonstrate & upscale solutions
- Track progress, monitor inequities in access to knowledge, research and care
- Engage with cancer community, citizens/patients & society at large

SPECIFIC OBJECTIVE 1: IMPROVE THE UNDERSTANDING OF CANCER

1) Establish the UNCAN.eu platform by 2023 (2021-2023)

Implementers: Academia, citizens/patients, SME/industry/charities, Member States

Calls for Proposals in 2022-2027 launched for:

2) Better understand healthy vs cancer cells at individual & populational level (2021-2028)

preclinical /early clinical stage

Implementers: Academia, citizens/patients, SME/industry/charities

3) Better understand cancer-patient molecular, cell, organ, organismal interactions (2023-2029)

preclinical /early clinical stage

Implementers: Academia, citizens/patients, SME/industry/charities

4) Determine the role of genetics in cancer (2024-2030)

stage phase I & II trials

Implementers: Academia, citizens/patients, SME/industry/charities

SPECIFIC OBJECTIVE 2: PREVENTION INCLUDING SCREENING AND EARLY DETECTION

Prevention:

1) Develop a one-stop cancer information centre on prevention (2022-2025)

Implementers: Academia, Member States, regions, citizens/patients, JRC, WHO/IARC

2) Boost research and innovation into risk assessment (2024-2027)

Stage: observational studies

Implementers: Academia, citizens/patients, SME/industry

3) Conduct implementation research on cancer prevention (2022-2030)

Stage: late stage clinical trials, observational studies

Implementers: Academia, citizens/patients, SME/industry

4) Establish synergies on prevention with other missions (2023-2026)

Implementers: Academia, SME/industry, citizens/patients, Member States, regions, health NGOs

SPECIFIC OBJECTIVE 2: PREVENTION INCLUDING SCREENING AND EARLY DETECTION

Screening and early Detection:

1) Optimise and improve access to existing screening programmes (2024-2029)

Implementers: Academia, Member States, regions, healthcare and insurance providers

2) Develop new methods and technologies for screening and early detection (2021-2026)

Stage: TRL4 and above

Implementers: Academia, citizens/patients, SME/industry

3) Develop early predictors / tests (2025-2030)

Stage: TRL 4 and above

Implementers: Academia, citizens/patients, SME/industry

SPECIFIC OBJECTIVE 3: OPTIMIZE DIAGNOSTICS AND TREATMENT

1) Support the creation of a Network of Comprehensive Cancer Infrastructures (CCIs) by 2025 (2021-2025)

Implementers: Academia, healthcare providers, citizens/patients, SME/industry, Member States

2) Develop twinning programmes (2024-2028)

Implementers: Academia, Member States, healthcare providers, citizens/patients

3) Develop a clinical trial programme on diagnostics (2023-2027)

Stage: Phase II / II clinical trials

Implementers: Academia, citizens/patients, SME/industry /charities, healthcare providers

4) Develop a clinical trial programme on treatments (2022-2023)

Stage: Phase II / II clinical trials

Implementers: Academia, citizens/patients, SME/industry /charities, healthcare providers

SPECIFIC OBJECTIVE 4: SUPPORT QUALITY OF LIFE

1) Collect and analyse data on today's unmet needs of cancer patients and survivors (2021-2025)

Implementers: Academia, citizens/patients, SME/industry/charities, healthcare and insurance providers

2) Set up of the European Cancer Patient Digital Centre (2021-2023)

Implementers: Academia, Member States, regions, citizens/patients, SME/industry, healthcare and insurance providers

3) Develop early predictors for quality of life (2024-2030)

Implementers: Academia, citizens/patients, SME/industry

4) Design monitoring programmes for survivors of childhood cancer (2021-2027)

Implementers: Academia, citizens/patients, SME/industry

HORIZON

EUROPE



**AUSBlick AUF DIE KOMMENDEN AUSSCHREIBUNGEN IM
ARBEITSPROGRAMM 2021/2022**



MISSIONEN ARBEITSPROGRAMM 2021/22

- Ein Arbeitsprogramm für alle 5 Missionen: [Arbeitsprogramm Missionen](#)
- Wurde im Juni 2021 erst-veröffentlicht und enthielt eine Reihe von Maßnahmen, die die Grundlage für die Umsetzung der Missionen bilden sollen („Preparatory Actions“)
- Update des Arbeitsprogramms 2021/22 mit Forschungsprojekten für Ende 2021 erwartet:
 - Ausschreibungsstart 22. Dezember
 - Einreichfristen von 24. März bis 26. April 2022
 - Einreichung kollaborativer, transnationaler Projekte (mind. 3 Partner aus EU/Assoz. Ländern)
 - Topic-Liste online, Draft des WPs auf Anfrage
 - [Missionen auf der FFG Webseite](#)

ÜBERSICHT DER MISSION CANCER AUSSCHREIBUNGEN (2021-2022)

- ✓ Horizon Europe Mission Work-Programme 2021 (Deadline 20 October 2021)
 - Topic HORIZON-MISS-2021-UNCAN-01-01: Preparing UNCAN.eu, a European initiative to understand cancer (budget: 3 million Euros). Action to develop a concept for a European platform, UNCAN.eu, using existing, relevant infrastructures, developing models and technologies of poorly understood cancers

- Update of Horizon Europe Mission Work Programme 2021:
 - 3 topics; budget: 125.65 million Euros
 - 1 procurement action to support mission (2 million Euros)
 - to be adopted and published end of December 2021
 - deadline for submission of proposals: 26 April 2022

- Mission Work Programme 2022
 - Total budget: 126 million Euros
 - preliminary info on planned topics

MISSION CANCER – WORK PROGRAMME 2021

Call	Budget in Millions of Euros	Call Opening	Call Deadline
HORIZON-MISS-2021-UNCAN-01: Preparing UNCAN.eu, a European initiative to understand cancer - CSA	3	22 June 2021	20 October 2021
HORIZON-MISS-2021-CANCER-02-01: Develop new methods and technologies for screening and early detection - RIA	60	22 December 2021	26 April 2022
HORIZON-MISS-2021-CANCER-02-02: Develop and validate a set of quality of life and patient preference measures for cancer patients and survivors - RIA	11	22 December 2021	26 April 2022
HORIZON-MISS-2021-CANCER-02-03: Better understand healthy versus cancer cells at the individual or population level through large-scale integration of research, health and non-health data (the UNCAN.eu concept) - RIA	54.65	22 December 2021	26 April 2022
Procurement Actions to support the Mission on Cancer: Optimise diagnosis and treatment (e.g. study on the comprehensiveness of cancer care infrastructures...), Quality of Life (e.g. study on feasibility, utility and sustainability of a virtual European cancer patient digital centre)	2	Not known yet	End 2021 / Beginning 2022

HORIZON-MISS-2021-CANCER-02-01: DEVELOP NEW METHODS AND TECHNOLOGIES FOR SCREENING AND EARLY DETECTION

Scope

- Develop and validate non-invasive (or minimally-invasive) cancer screening and detection methodologies, including *'integrated diagnostics'* (based on existing screening and early detection methods, technologies) & *digital technologies*
- Assess the potential uptake in national health systems, identify target population, consider implementation needs
- Use of living labs or other implementation research models, support end-user engagement
- Influence of various factors (genetic risk, socio-economic status, age, life style, sex, environment, ect.) and differences between countries taken into account

Disciplines addressed

Radiology, imaging, pathology, genetics, genomics, phenotyping, lab testing, IT, AI, machine learning, SSH-expertise etc.

Specific Conditions

Type of Action: Research and Innovation Action

Indicative Budget: 60 Mio Euro

Expected EU contribution per project: 4-15 Mio Euro

Expected stage at project start: Technological Readiness Level 4 and above

10 projects to be funded

HORIZON-MISS-2021-CANCER-02-01: DEVELOP NEW METHODS AND TECHNOLOGIES FOR SCREENING AND EARLY DETECTION

Target Groups	Planned expected outcomes
Healthy citizens and cancer patients	benefit from faster, earlier, more precise, personalised, accessible and affordable screening and early detection of cancer
Health care professionals	deliver earlier, faster, more precise screening and early detection of cancer
Health policy makers	evidence to allow reviewing their population-based screening programmes include new, evidence-based screening and early detection methods, technologies and solutions

HORIZON-MISS-2021-CANCER-02-02: DEVELOP AND VALIDATE A SET OF QUALITY OF LIFE AND PATIENT PREFERENCE MEASURES FOR CANCER PATIENTS AND SURVIVORS

Goal

- Development of a goal of framework of newly defined, harmonised and systematic surveys
- Collection of new and update of existing quality of life data and registries information with digital tools
- Launch of surveys regularly across all countries → reviewed with researchers, care providers, health insurance companies, industry, policy makers

Specific Conditions

Type of Action: Research and Innovation Action

Indicative Budget: 11 Mio Euro

Expected EU contribution per project: 11 Mio Euro

1 project to be funded

HORIZON-MISS-2021-CANCER-02-02: DEVELOP AND VALIDATE A SET OF QUALITY OF LIFE AND PATIENT PREFERENCE MEASURES FOR CANCER PATIENTS AND SURVIVORS

Scope

- Conduct analyses of existing quality of life care data from studies, surveys and registries together with patients, focus on patients' needs (return to work!)
- Develop quality of life measurement tools and approaches with patients, communities and multidisciplinary research teams
- Establish metrics, covering subjective perceptions of positive & negative aspects of cancer patients' symptoms
- Prepare and conduct a pilot of newly defined, harmonised and systematic quality of life surveys → basis for a comprehensive comparison of the quality of life of cancer patients and survivors → basis for future data collection
- Influence of various factors (genetic risk, socio-economic status, life style, sex, environment, ect.) to be taken into account
- Validation of most promising quality of life and preference measures and metrics

Specific Conditions

Type of Action: Research and Innovation Action

Indicative Budget: 11 Mio Euro

Expected EU contribution per project: 11 Mio Euro

1 project to be funded

Survey results including validation of the metrics available within two years from the start of the project!

HORIZON-MISS-2021-CANCER-02-02: DEVELOP AND VALIDATE A SET OF QUALITY OF LIFE AND PATIENT PREFERENCE MEASURES FOR CANCER PATIENTS AND SURVIVORS

Target Groups	Planned expected outcomes
Cancer patients, survivors and caregivers	benefit from enhanced quality of life, more effective & less burdensome treatments, better supportive care & counselling approaches
Health care professionals, supportive workers, counsellors and industry	better aware of (unmet) needs, expectations and preferences of cancer patients, survivors and their relatives
Regulators and institutions	have a set of metrics, include in decision making about risks, benefits of new health interventions
Health Policy Makers	have a set of metrics to include in health information and performance measurement systems
Labour market, social protection policy makers	Additional evidence for design of policies -> facilitating return to work, active participation in society

HORIZON-MISS-2021-CANCER-02-03: BETTER UNDERSTAND THE IMPACT OF RISK FACTORS AND HEALTH DETERMINANTS ON THE DEVELOPMENT AND PROGRESSION OF CANCER

Considering

- Internal and external risk factors
- Progression of cancer including metastasis
- Poorly understood cancers and cancer subtypes (any stage)
- Children and adolescents included

Scope

- Develop a systematic understanding of cellular processes with a focus on the transition from a healthy state to cancer initiation and progression
- Demonstrate access to and use of multiple comprehensive databases in and well beyond health research and health domains → build on longitudinal cohorts, case-control studies, biobanks, registries etc.
- Analyse and integrate existing knowledge and high-quality data from biomedical and clinical studies (use computer modelling, AI, machine learning etc)
- Influence of various factors (in utero, early life factors, environment, genetic, epigenetic risk, socio-economic, etc.) to be taken into account

Specific Conditions

Type of Action: Research and Innovation Action

Indicative Budget: 54,65 Mio Euro

Expected EU contribution per project: 4-15 Mio Euro

6 Projects to be funded

HORIZON-MISS-2021-CANCER-02-03: BETTER UNDERSTAND THE IMPACT OF RISK FACTORS AND HEALTH DETERMINANTS ON THE DEVELOPMENT AND PROGRESSION OF CANCER

Target Groups	Planned expected outcomes
Researchers and health professionals	understand which risk factors and determinants spur the development and progression of cancer and how → basis for design & optimisation prevention, screening and early detection interventions
Researchers and innovators from different disciplines and sectors	producing, integrating and correlating comprehensive data from multiple sources → support development of UNCAN.eu
Health Policy Makers	use the improved understanding of risk factors and determinants in the design of cancer-related health policies

Synergies with other EU-funded initiatives like:

Knowledge Centre on Cancer, Healthy Cloud, EOSC-Life, European Health Data Space (EHDS) and many more (see topic text!)

PROCUREMENT ACTIONS TO SUPPORT THE MISSION ON CANCER

Optimise diagnosis and treatment

A study on the comprehensiveness of cancer care infrastructures in EU-27 & assoc. countries:

- assess national and regional capacity to support cancer control
- include quality standards, staffing and resources and economic aspects

Quality of Life:

A study on feasibility, utility and sustainability of a virtual European cancer patient digital centre, references to

- European Health Data Space
- Digital Europe
- ESFRI Infrastructures
- JRC Work Programmes

Specific Conditions

Type of Action: Public Procurement

Indicative Budget: 2 Mio Euro

Indicative timetable: 4th Quarter 2021– 2nd Quarter 2022

MISSION CANCER – WORK PROGRAMME 2022 – PRELIMINARY INFORMATION

Geplante Inhalte:

- Improving and upscaling primary prevention of cancer through implementation research
- Strengthen Comprehensive Cancer Infrastructures
- Pragmatic clinical trials to optimise treatments for cancer patients
- Towards the creation of a European Cancer Patient Digital Centre
- Creation of national mission hubs supporting the Mission on Cancer
- European Observatory on Health Systems and Policies
- Procurement Actions to support the Mission

Geplante Call-Öffnung: Mai 2022

Geplante Deadline: September 2022

WEITERFÜHRENDE LINKS

Mission Cancer

- [Mission Cancer in Horizon Europe](#)
- [Mission Cancer Implementation Plan](#)
- [Europäischer Krebsplan](#)
- [EU4Health Programm](#)
- [Digital Europe Programme](#)

MAIN SERVICES

Contact us

by email, phone call...if you have any questions!

[Register for our newsletter](#)

Check of project idea

send us your “One pager” and we can discuss by phone or video-call

FFG Academy trainings

participate in our proposal writing trainings
=> next training: 25-26 January 2022!

Proposalcheck

send us your proposal (as advanced as possible) and we give you written feedback

Join the community

Website, newsletter, events => stay up to date!

[Video FFG Services](#)

[Online “Help yourself” Informationspakete](#)

VIELEN DANK FÜR IHRE AUFMERKSAMKEIT!

Ines Haberl

Österreichische Forschungsförderungsgesellschaft
Sensengasse 1, A-1090 Wien

T +43 (0) 5 77 55 – 4103

M +43 (0) 664 88 54 021

ines.haberl@ffg.at

www.ffg.at